Correction of sleep disorders in EMERCOM employees: The results of using long-acting melatonin
https://doi.org/10.14412/2074-2711-2017-1-67-70
Abstract
Objective: to evaluate the efficacy of long-acting melatonin in EMERCOM employees with sleep disorders (insomnia) associated with desynchronosis.
Patients and methods. 30 patients (EMERCOM employees) having manifestations of desynchronosis-associated insomnia were examined using the following tests and questionnaires: the short-term verbal memory test (five words test); the modified point subjective sleep characteristics scale; the Hospital Anxiety and Depression Scale; the Screening Dysfunctional Beliefs and Attitudes Scale; the symbolic-digital coding test; individual sleep diaries.
Results. According to the tests and questionnaires, the treatment resulted in a statistically significant improvement in sleep quality and indicators of short-term memory and cognitive functions (attention concentration) and a reduction in anxiety and depression.
Conclusion. Long-acting melatonin has a good safety profile and can be recommended as a first-line drug to treat desynchronosis-associated sleep disorders.
About the Authors
Yu. B. Slizkova
Central Polyclinic Seventy-Two, Ministry of the Russian Federation for Civil Defense, Emergencies, and Elimination of Consequences of Natural Disasters (EMERCOM)
Russian Federation
1, Vatutin St., Moscow 121357
Russian Federation
1, Vatutin St., Moscow 121357
V. A. Bryuzgin
Central Polyclinic Seventy-Two, Ministry of the Russian Federation for Civil Defense, Emergencies, and Elimination of Consequences of Natural Disasters (EMERCOM)
Russian Federation
1, Vatutin St., Moscow 121357
Russian Federation
1, Vatutin St., Moscow 121357
References
1. Grewal R, Doghramji K. Epidemiology of insomnia. In: Attarrian HP, Schuman C, editors. Clinical Handbook of insomnia. Springer Science+Business Media, LLC; 2010. P. 13-22.
2. Morin CM, Jarrin DC. Epidemiology of insomnia. Prevalence Course, Risk Factors, and Public Health Burden. Sleep Med Clin. 2013; (8):281-97.
3. Shutte-Rodin S, Broch I, Buy D, et al. Clinical guideline for the evaluation and management of chronic insomnia in adults. J Clin Sleep Med. 2008 Oct 15;4(5):487-504.
4. Wilson SJ, Nutt DJ, Alford C, et al. British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders. J Psychopharmacol. 2010 Nov;24(11): 1577-601. doi: 10.1177/0269881110379307. Epub 2010 Sep 2.
5. Левин ЯИ. Мелатонин (Мелаксен) в терапии инсомнии. Русский медицинский журнал. 2005;(7):498–500. [Levin YaI. Melatonin (Melaxen) in the treatment of insomnia. Russkii meditsinskii zhurnal. 2005;(7): 498–500. (In Russ.)].
6. Тхостов АШ, Рассказова ЕИ. Шкала дисфункциональных убеждений в отношении сна. Учебно-методическое пособие. Москва: Издательство МГУ; 2007. 33 с. [Tkhostov ASh, Rasskazova EI. Shkala disfunktsional'nykh ubezhdenii v otnoshenii sna. Uchebno- metodicheskoe posobie [Scale of dysfunctional beliefs about sleep. Textbook]. Moscow: Izdatel'stvo MGU; 2007. 33 p.]
7. Zigmond AC, Snaith RP. The Hospital Anxiety And Depression scale. Acta Psychiatr Scand. 1983 Jun;67(6):361-70.
8. Датиева ВК, Ляшенко ЕА, Левин ОС. Применение мелатонина при нарушении сна. Современная терапия в психиатрии и неврологии. 2015;(1):36-9. [Datieva VK, Lyashenko EA, Levin OS. The use of melatonin for sleep disorders. Sovremennaya terapiya v psikhiatrii i nevrologii. 2015;(1):36-9. (In Russ.)].
9. Ковров ГВ, Агальцов МВ, Сукмарова ЗН. Эффективность мелатонина пролонгированного высвобождения при первичных нарушениях сна у пациентов старше 55 лет. Неврология, нейропсихиатрия, психосоматика. 2016;8(2):24-30. [Kovrov GV, Agal'tsov MV, Sukmarova ZN. Effectiveness of prolongedrelease melatonin in improving quality of sleep in patients aged 55 or over. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2016;8(2): 24-30. (In Russ.)]. DOI: 10.14412/2074-2711-2016-2-24-30
10. Котова ОВ. Роль мелатонина в лечении депрессии. Неврология, психиатрия, психосоматика. 2011;3(2):85-8. [Kotova OV. Role of melatonin in the treatment of depression. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2011;3(2):85-8. (In Russ.)]. DOI: 10.14412/2074-2711-2011-153
11. Захаров ВВ. Нарушение памяти и сна в амбулаторной практике. Неврология, Психиатрия, психосоматика. 2013;5(1):54-8. [Zakharov VV. Memory and sleep disorders in an outpatient setting. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2013;5(1):54-8. (In Russ.)]. DOI: 10.14412/2074-2711- 2013-2400
12. Clay E, Falissard B, Moore N, Toumi M. Contribution of prolonged-release melatonin and anti-benzodiazepine campaigns to the reduction of benzodiazepine and Z-drugs consumption in nine European countries. Eur J Clin Pharmacol. 2013 Apr;69(4):1-10. doi: 10.1007/s00228-012-1424-1. Epub 2012 Nov 1.
13. Seabra ML, Bignotto M, Pinto LR Jr, Tufik S. Randomized, double-blind clinical trial, controlled with placebo, of the toxicology of chronic melatonin treatment. J Pineal Res. 2000 Nov;29(4):193-200.
14. Левин ОС, редактор. Основные лекарственные средства, применяемые в неврологии: справочник. 3-е изд. Москва: МЕДпресс-информ; 2009. 352 с. [Levin OS, editor. Osnovnye lekarstvennye sredstva, primenyaemye v nevrologii: spravochnik [Essential drugs used in neurology: a guide]. 3rd ed. Moscow: MEDpress-inform; 2009. 352 p.]
15. Яхно НН. Отчет о клинической эффективности препарата МЕЛАКСЕН фирмы Unipharm–USA (США) при лечении инсомний. Лечащий врач. 1999;(10):26–7. [Yakhno NN. Report on the clinical effectiveness of the drug MELAXEN by Unipharm–USA (USA) in the treatment of insomnia. Lechashchii vrach. 1999; (10):26–7. (In Russ.)].
16. Lemoine P, Wade AG, Katz A, et al. Efficacy and safety of prolonged-release melatonin for insomnia in middle-aged and elderly patients with hypertension: a combined analysis of controlled clinical trials. Integr Blood Press Control. 2012;5:9-17. doi: 10.2147/IBPC.S27240. Epub 2012 Jan 25.
17. Beaumont M, Batejat D, Pierard C, et al. Caffeine or melatonin effects on sleep and sleepiness after rapid eastward transmeridian travel. J Appl Physiol (1985). 2004 Jan;96(1):50-8. Epub 2003 Sep 5.
18. Wang JZ, Wang ZF. Role of melatonin in Alzheimer-like neurodegeneration. Acta Pharmacol Sin. 2006 Jan;27(1):41-9.
19. Быков ЮВ, Ханнанова АН, Беккер РА. Мелатонин и бензодиазепины в лечении инсомнии: за и против (обзор литературы). В мире научных открытий. 2016;(7):60-82. [Bykov YuV, Khannanova AN, Bekker RA. Melatonin and benzodiazepines in the treatment of insomnia: for and against (literature review). V mire nauchnykh otkrytii. 2016;(7): 60-82. (In Russ.)].
20. Ерышев ОФ, Анипченко АВ, Андреева НЭ, Андрианов ФВ. Открытое и несравнительное исследование эффективности и безопасности мелаксена при лечении нарушений сна у пациентов с алкогольной зависимостью в период воздержания от употребления алкоголя. Журнал неврологии и психиатрии им. С.С. Корсакова. 2013;(6):47–53. [Eryshev OF, Anipchenko AV, Andreeva NE, Andrianov FV. Open and non-comparative study of the efficacy and safety of melaxen in the treatment of sleep disorders in patients with alcohol dependence in the period of abstinence from alcohol. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2013;(6):47–53. (In Russ.)].
Review
For citations:
Slizkova YB, Bryuzgin VA. Correction of sleep disorders in EMERCOM employees: The results of using long-acting melatonin. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2017;9(1):67-70. (In Russ.) https://doi.org/10.14412/2074-2711-2017-1-67-70
Views:
554
Email this article 